On June 25, Abivax S.A. declined 5.84% overnight, trading at $87.11/share, with turnover of $339,100. The decline reflects continued market uncertainty surrounding the safety profile of the company's lead drug candidate obefazimod.

The core issue stems from the Phase 3 ABTECT maintenance trial, where multiple cancer cases emerged in the 50mg dose group, triggering an initial crash from approximately $130 to around $70 — a decline of nearly 50%. While some investors subsequently argued that the cancer cases were more likely age-related and that the initial reaction was excessive, driving a partial rebound above $100, the stock has since resumed its downward trajectory. Market consensus on the safety dispute remains divided, and technical rebound momentum continues to weaken.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases, with obefazimod currently in Phase 3 trials for moderately to severely active ulcerative colitis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)